OrganaBio expands rapid PBMC processing to San Diego at Excellos Labs
New facility enhances time-sensitive clinical sample processing for cell therapy workflows
15 Jul 2026Industry news
OrganaBio, LLC has opened a new peripheral blood mononuclear cell (PBMC) processing and cryopreservation laboratory at Excellos Labs in San Diego, California. The new facility extends OrganaBio’s rapid, time-sensitive PBMC isolation services to one of the largest cell and gene therapy hubs in the United States, enabling clinical trial sponsors and cell therapy developers in Southern California to access fast, high-viability clinical sample processing.
Expansion of rapid PBMC isolation in San Diego
The launch of the San Diego laboratory expands OrganaBio’s time-sensitive PBMC isolation capabilities into the heart of one of the most concentrated advanced therapy ecosystems in the world. Located near leading research institutions, clinical research centers, and cell and gene therapy developers, the Excellos Labs site is positioned to support clinical sites that require rapid processing of clinical trial samples.
This new laboratory is the first expansion of services through Excellos Labs since OrganaBio’s acquisition of Excellos in May 2026, further strengthening OrganaBio’s nationwide network for cell therapy developers and clinical trial sponsors.
Fast turnaround times and high PBMC quality
With the San Diego expansion, clinical trial sponsors can have cryopreserved PBMC samples within three to four hours of collection, a critical factor for maintaining cell viability and function. OrganaBio delivers industry-leading turnaround times and quality metrics, with an average PBMC viability of 99.1% and PBMC recovery exceeding 2.9 x 10^6/mL.
These performance metrics are supported by a rigorously trained team qualified across multiple internal and sponsor-specific standard operating procedures (SOPs). OrganaBio’s operators routinely isolate PBMCs from leukopaks and whole blood in support of the company’s cellular starting material business.
Consistent PBMC processing across a national network
OrganaBio’s operators travel between sites to ensure consistency, reproducibility, and quality across the company’s processing network. By integrating Excellos Labs’ San Diego footprint, OrganaBio now operates three West Coast laboratories in addition to its Miami headquarters.
This expanded infrastructure provides coast-to-coast coverage for sponsors as their clinical programs scale and expand geographically, ensuring harmonized PBMC isolation and cryopreservation processes across multiple regions.
Strategic benefits of the Excellos Labs integration
“Standing up rapid PBMC processing at Excellos Labs means that sponsors running trials across Southern California can now access the same high-viability sample processing our partners rely on coast to coast, with no tradeoff between speed and quality,” said Justin Irizarry, CEO of OrganaBio.
“This is only the first example of the many cross-organizational benefits we can leverage to enhance our partners’ experience, as we continue to merge operations between OrganaBio and Excellos Labs.”
By combining OrganaBio’s established cell isolation expertise with Excellos Labs’ San Diego presence, the company is enhancing support for cell and gene therapy developers who depend on rapid, reliable PBMC processing for clinical trials and translational research.
Supporting next-generation cell and gene therapies
With operations now spanning Miami, Irvine, the San Francisco Bay Area, and San Diego, OrganaBio continues to advance its mission to accelerate access to high-quality donor materials and manufacturing solutions. The expanded PBMC processing network is designed to support the rapid development and delivery of next-generation cell and gene therapies by providing timely, high-viability clinical samples to sponsors and developers.
Want the latest science news straight to your inbox? Become a SelectScience member for free today>>
Frequently asked questions
How does OrganaBio’s new San Diego PBMC laboratory at Excellos Labs support cell and gene therapy clinical trials?
OrganaBio’s new PBMC processing and cryopreservation lab at Excellos Labs in San Diego enables clinical trial sponsors and cell and gene therapy developers in Southern California to access rapid, high-viability PBMC isolation. Located near major research institutions and clinical centers, the facility supports time-sensitive clinical trial sample processing with harmonized procedures across OrganaBio’s national network.
What performance metrics does OrganaBio achieve for PBMC isolation and cryopreservation in San Diego?
At the San Diego Excellos Labs site, OrganaBio provides cryopreserved PBMC samples within three to four hours of collection, helping maintain cell viability and function. The company reports an average PBMC viability of 99.1% and PBMC recovery exceeding 2.9 x 10^6/mL, supported by rigorously trained operators qualified on internal and sponsor-specific SOPs.
How does OrganaBio’s integration of Excellos Labs expand its nationwide PBMC processing network?
OrganaBio’s acquisition and integration of Excellos Labs in May 2026 added a San Diego PBMC processing hub to its existing Miami, Irvine, and San Francisco Bay Area operations. Operators travel between sites to ensure consistent, reproducible PBMC isolation and cryopreservation, providing coast-to-coast coverage for cell and gene therapy developers and clinical trial sponsors as their programs scale geographically.